×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Eleanor Miller, M.S.N., RN, OCN, CBCN
Nominee for CURE®’s 2019 Extraordinary Healer® award, oncology nurse Megan Roy’s insight is valued and trusted by both patients and her team, making care processes smooth no matter whether she worked directly with patients or not.
 
Alexandra Guadagno
From today’s top performers and athletes to surprising findings about prostate cancer treatment, here’s what is making headlines in the cancer space this week. 
 
Lowell Hart
With new ways to treat chemotherapy-induced side effects, it seems that chemotherapy, combined with checkpoint inhibitors, is here to stay for the foreseeable future, according to one expert.
R. Donald Harvey
One expert weighs the benefits and drawbacks of expanding clinical trials to be more inclusive and reflective of the general patient population with cancer.
Jennifer King
Studies show that the social stigma can actually affect a patient’s level of care and lead to worse health outcomes.
Dr. Daniel McFarland
Tumor mutation burden may be an independent predictor of developing depression in patients with lung cancer, according to Dr. Daniel McFarland.
Alexandra Guadagno
The FDA has approved Zirabev, a biosimilar to Avastin, for the treatment of five types of cancer: colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Jessica Skarzynski
The growing use of telecommunication and technology to provide health care – or telemedicine – offers many advantages, but also comes with challenges, says one expert.
Dr. Lowell Hart
Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.
Alexandra Guadagno
From cancer-sniffing dogs to music therapy for pain, here’s what is making headlines in the cancer space this week.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other